On His Way Out

The CEO of Biogen Idec, James Mullen, will be leaving the company in June after "seven turbulent years," says Fierce Biotech. During his tenure, Mullen oversaw the approval and marketing of Tysabr, to treat multiple sclerosis, which was then linked to rare, deadly brain infections.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.